Summary: Since 2018 the clinical recommendations for the therapy of type 2 has changed significantly. The series of cardiovascular outcome trials assessing cardiovascular safety on new antidiabetes medications, mostly SGLT-2 inhibitors and GLP-1 receptor agonists revealed that these agents besides plasma glucose lowering lead to the reduction of cardiovascular risk, more specifically lower the risk of hospitalization for heart failure with reduced or preserved ejection fraction and slow down the progress of chronic renal failure, and in case of empagliflozin – reduce the risk of cardiovascular death. At present SGLT-2 inhibitors and GLP-1 receptor analogs should be used as widely as possible, and if their use is not efficacious enough in terms of lowering blood glucose, other agents including metformin, sulfonylureas, DPP-4 inhibitors, pioglitazone or insulin may be added.